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Abstract 
Background: Asthma affects an estimated 300 million people worldwide with the condition associated with signifi‑
cant healthcare utilisation costs and a large impact on patient quality of life. The SQ® HDM SLIT‑tablet (ACARIZAX®, 
Hørsholm, Denmark) is a sublingually administered allergy immunotherapy tablet for house dust mite allergic asthma 
and allergic rhinitis and has recently been licensed in Europe.
Objective: To assess the cost‑effectiveness of ACARIZAX plus pharmacotherapy versus placebo plus pharmaco‑
therapy in patients with house dust mite allergic asthma that is uncontrolled by inhaled corticosteroids, in a German 
setting. Eligible patients should also have symptoms of mild to severe allergic rhinitis.
Methods: A cost utility analysis was undertaken, based on the results of a European phase III randomised controlled 
trial, in which ACARIZAX was compared with placebo with both treatment groups also receiving pharmacotherapy 
in the form of inhaled corticosteroids and short‑acting β2‑agonists. Cost and quality‑adjusted life years from the trial 
were extrapolated over a nine year time horizon and the incremental cost‑effectiveness ratio calculated to compare 
treatment options.
Results: ACARIZAX plus pharmacotherapy was estimated to generate 6.16 quality‑adjusted life years per patient at 
a cost of €5658, compared with 5.50 quality‑adjusted life years (QALYs) at a cost of €2985 for placebo plus pharmaco‑
therapy. This equated to an incremental cost of €2673, incremental QALYs of 0.66 and an incremental cost‑effective‑
ness ratio (ICER) of €4041. The ICER was, therefore, substantially lower than the €40,000 willingness‑to‑pay threshold 
per QALY adopted for the analysis. Deterministic sensitivity analyses indicate the results are most sensitive to the 
utility score of ACARIZAX patients during years 2 and 3 of treatment.
Conclusion: This analysis indicates that ACARIZAX plus pharmacotherapy is cost‑effective compared with placebo 
plus pharmacotherapy for house dust mite allergic asthma patients in Germany. If a disease‑modifying effect can be 
proven the results of this analysis may underestimate the true benefits of ACARIZAX.
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Background
Asthma is a chronic global health problem having a sig-
nificantly detrimental effect on quality of life and is often 
associated with significant healthcare utilisation costs. 
It is estimated that asthma affects 30 million people in 
Europe and up to 300 million people worldwide, with 
prevalence expected to rise [1, 2]. In Germany, asthma 
has been estimated to affect approximately 7  % of the 
population [3]. Most asthma cases are due to allergic 
conditions with previous research showing that over 90 % 
of all allergic asthma patients display symptoms that cor-
relate with allergic rhinitis [4].
Although the disease does not exhibit high mortal-
ity rates, the loss in quality of life is significant, with 
both physical and psychological dimensions found to 
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costs to the healthcare system and wider society. One 
European-wide cost-of-illness study found that the mean 
annual costs of asthma in 2010, including both direct and 
indirect costs, were €509 and €2281 for controlled and 
uncontrolled asthma patients respectively [7]. The total 
asthma burden in Germany was estimated to be €3.3 bil-
lion in 2008 [3].
The SQ® HDM SLIT-tablet (ACARIZAX®, ALK, Hør-
sholm, Denmark) is a recently developed allergy immu-
notherapy (AIT) tablet, targeted specifically at house dust 
mite (HDM) allergens. It is a sublingual treatment option 
for HDM allergic asthma patients already taking pharma-
cotherapy whose symptoms are not well controlled, and 
is a 1:1 mixture of allergen extract from Dermatophagoi-
des pteronyssinus and Dermatophagoides farinae [8]. The 
objective of this analysis was to assess the cost-effective-
ness of ACARIZAX from a German societal perspective.
Methods
Design
A cost-utility analysis was undertaken based on the 
results of a double-blinded phase III randomised con-
trolled trial. The MT-04 trial was conducted across 
13 European countries, with the primary objective of 
comparing the efficacy of ACARIZAX with placebo in 
patients with HDM allergic asthma, as measured by a 
reduction in the risk of asthma exacerbation. Eligible 
patients were adults, sensitised to HDM and not well 
controlled by inhaled corticosteroids (ICS; equivalent 
to budesonide, 400–1200 μg) at inclusion. Furthermore, 
they could have multiple sensitizations but a relevant 
clinical history of perennial allergic asthma or rhinitis 
caused by other allergens to which the patients were reg-
ularly exposed led to exclusion as this may have caused 
symptoms to arise in the efficacy period that would inter-
fere with the trial results [9]. Patient characteristics are 
summarised in Table  1. Two treatment groups (6 SQ-
HDM and 12 SQ-HDM), and one control group (pla-
cebo) were included in the trial to investigate different 
therapy doses, with the 12 SQ-HDM group considered 
here. Patient diagnosis took place during the trial screen-
ing period. Following screening there was a 7–13 month 
treatment maintenance period, in which patients in 
both arms were the given their allocated treatment plus 
pharmacotherapy in the form of ICS and short-acting 
β2-agonist (SABA). Patients could also be given oral 
steroids to treat severe acute asthma symptoms or to 
restrict the deterioration of asthma symptoms. Follow-
ing the treatment maintenance period, the daily ICS dose 
was reduced by 50 % for 3 months and then removed for 
patients who did not experience an asthma exacerbation. 
The treatment maintenance period was adopted for the 
analysis as it was judged to be better aligned with present 
clinical practice. A more comprehensive description of 
the trial design has been published previously [9]. Based 
on the setup of MT-04, two treatment options have 
been incorporated into the cost-utility analysis: ACARI-
ZAX plus pharmacotherapy (ACARIZAX henceforth) 
and placebo plus pharmacotherapy (pharmacotherapy 
henceforth).
Healthcare resource use
Within MT-04, patients recorded medication use using 
electronic diaries during the last 4 weeks of the treatment 
maintenance period. Physician and emergency room vis-
its were also recorded by trial investigators at each visit. 
In the analysis, all resources recorded within MT-04 were 
combined with relevant unit costs from a German per-
spective, to estimate mean patient costs over a one year 
time horizon. The cost of ACARIZAX was also included, 
with a patient requiring one tablet per day. ACARIZAX 
is suitable for home treatment, although the first tab-
let should be taken under the surveillance of a physi-
cian. This additional visit was also incorporated into the 
model. Healthcare resource use values implemented in 
the analysis are summarised in Table 2.
The analysis was also run with sick days considered, 
to capture the impact of indirect costs. Within MT-04, 
the impact of asthma on productivity was captured via 
the administration of the work productivity and activity 
impairment (WPAI) questionnaire. The WPAI is a well-
validated instrument that measures absenteeism, pres-
enteeism and impairments in unpaid activity over the 
previous seven day period [10].
Table 1 Summary of patient characteristics from MT-04
AA allergic asthma, HDM house dust mite, SD standard deviation
a Classification system based on GINA, Masoli et al. [2]
Placebo ACARIZAX
No. of subjects 277 282
Sex (%)
 Male 151 (55 %) 147 (52 %)
 Female 126 (45 %) 135 (48 %)
Mean age (SD) 33.0 (12.2) 37 (11.6)
Ethnic origin (%)
 Caucasian 273 (99 %) 277 (98 %)
 Other 4 (1 %) 5 (2 %)
Mean years with HDM AA (SD) 13.3 (10.6) 12.9 (11.5)
Control level at randomisation (%)a
Controlled 0 (0 %) 0 (0 %)
 Partly controlled 200 (72 %) 200 (71 %)
 Uncontrolled 77 (28 %) 82 (29 %)
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Patient quality of life
The impact of allergic asthma on patient health-related 
quality of life (HRQoL) was captured. Patient reported 
health outcomes were used to elicit utility scores; which 
are the valuing of health on a scale of 0–1, with 0 rep-
resenting health states equivalent to death and 1 repre-
senting full health. Quality-adjusted life years (QALYs) 
combine utility values and time to determine HRQoL 
over time. A patient who experiences one year in full 
health, (i.e. with a utility value of 1), would gain 1 QALY. 
Similarly, a patient who experiences 2 years with health 
valued at 0.5 would gain 1 QALY [11]. Utilities have been 
used to estimate QALYs for patients in both treatment 
groups.
Utility values used in the model were taken from the 
end of the treatment maintenance period in MT-04 (i.e. 
before ICS reduction and removal). Within the trial the 
SF-36 health survey was used to measure patient utility. 
For values used within the analysis, the data was cor-
rected for baseline to determine between group differ-
ences at the end of the treatment maintenance period. 
These utility scores are summarised in Table 3.
Pharmacoeconomic analysis
To assess the long-term impact of ACARIZAX on the 
healthcare system and patient HRQoL, costs and QALYs 
from MT-04 have been extrapolated over a nine-year 
time horizon. For this extrapolation, costs that occurred 
during year one are applied equally across all years. To 
examine the impact of treatment on patient health, QALY 
scores were altered using an annual rate of change in util-
ity (i.e. quality of life). There is evidence that AIT may 
have both a curative and preventative impact on respira-
tory allergies, equating to a long-term treatment effect 
[12–14]. Evidence specific to GRAZAX® therapy, shows 
that the treatment has a disease-modifying effect, as 
patients receive clinical benefit for at least 5 years despite 
treatment only lasting 3 years [15]. In the analysis it has 
been assumed that there will be a 5 % increase in utility 
for ACARIZAX patients during years two and three of 
treatment, based on the assumption patients will con-
tinue to receive a clinical benefit from treatment. Alter-
natively, for pharmacotherapy patients it is assumed that 
patient health remains stable, based on the assumption 
that the improvement that was observed during the trial 
for pharmacotherapy patients will remain throughout 
this period. Following the treatment period it is assumed 
that both patient groups remain stable for years four and 
five (i.e. 2  years after discontinuation of treatment), fol-
lowed by a 5 % decline in health during years 6–9.
Based on these assumptions, costs and QALYs have been 
estimated for both treatment groups over the nine-year 
time horizon and an assessment of the cost-effectiveness 
undertaken. Cost-effectiveness was defined using the incre-
mental cost-effectiveness ratio (ICER) of ACARIZAX in 
addition to pharmacotherapy versus pharmacotherapy 
alone. To estimate the cost-effectiveness of an interven-
tion to society as a whole, it is necessary to compare the 
Table 2 Summary of cost and resource use inputs incorporated in the analysis
Three drugs and two other medical resources were included as parameters in the analysis. Resource use was based on data recorded in MT‑04 and, therefore, they 
relate specifically to allergic asthma patients. The values have been multiplied by the unit price of each resource to generate total costs. These costs were applied to a 




Resource Unit price Annual resource use Total cost
ACARIZAX Pharmacotherapy ACARIZAX Pharmacotherapy
ACARIZAX tableta €2.53 365 0 €923 €0
GP visitsb €29.35 0.175 0.105 €5.13 €3.07
Emergency room visitsb €74.96 0.010 0.025 €0.75 €1.89
ICS daily dose (μg)c €18.14 563 555 €373 €363
SABA intake (doses)c €22.15 266 297 €9.82 €10.96
Table 3 Summary of  utility values applied to  patients 
in the analysis
Within MT‑04 patient utility was measured using the SF‑36 survey instrument. 
There was a statistically significant difference in utility change (i.e. a 
measurement of patient quality of life) from baseline to the end of the treatment 
maintenance period in MT‑04 between ACARIZAX and placebo (p < 0.05). 
These values were applied to the mean utility score at baseline for all patients, 
to estimate the values that were applied at baseline in the analysis. Overall, 
ACARIZAX patients had a greater quality of life compared to placebo patients, at 




Change from baseline Utility adopted 
in analysis
Placebo ACARIZAX p value Placebo ACARIZAX
0.736 0.0059 0.0315 0.0318 0.742 0.768
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ICER against a willingness-to-pay threshold. This allows 
the value of one QALY to society to be defined in mon-
etary terms. In Germany, rationing decisions are made by 
Gemeinsamer Bundesausschuss (G-BA) on a case-by-case 
basis and, therefore, there is no defined threshold [16]. 
However in the United Kingdom, the National Institute 
for Health and Care Excellence (NICE), a world leader in 
national health technology assessments, uses a threshold of 
£20,000 to £30,000 per QALY (€27,473 to €41,209) [17]. For 
an intervention to be cost-effective, the ICER should fall 
within or below this threshold. For this analysis, a threshold 
value of €40,000 (~£30,000) has been used. This means that 
compared with pharmacotherapy only, ACARIZAX should 
generate one QALY at a cost less than or equal to €40,000.
Because a nine-year time horizon has been adopted, 
cost and QALY values were discounted using an annual 
discount rate of 3 %, in line with German guidelines [18].
Uncertainty analysis
To investigate the impact of changes in long term patient 
utility, two scenarios have been tested alongside the base 
case analysis. The rate of utility change for ACARIZAX 
and pharmacotherapy in the two scenarios are depicted 
graphically in Fig.  1. In short, within scenario one it is 
assumed that utilities (i.e. quality of life) remain stable 
during the treatment period (i.e. years 2–3), followed by 
a 5 % decline for all subsequent years, for both treatment 
groups. This is to test the impact of a decline in health as 
soon as treatment is stopped, an unfavourable scenario. 
In scenario two it is assumed that ACARIZAX patients 
have a small 5  % increase in utility for years two and 
three, followed by stability for all remaining years, whilst 
the utility for pharmacotherapy remains stable for the 
full time horizon. This scenario has been implemented to 
test the impact of a lasting disease-modifying effect for 
ACARIZAX that leads to long-term improvements in 
patient health.
In order to account for first-order uncertainty around 
the data used for input parameter values, one-way 
deterministic sensitivity has also been undertaken. This 
involves altering the value used for individual parameters 
within realistic ranges, to assess the impact on the mod-
el’s results.
Results
The overall setup of the analysis and key results are pre-
sented in Fig. 2. The results of the base case analysis indi-
cate that, over the nine year time horizon, ACARIZAX 
in addition to pharmacotherapy leads to a total of 6.16 







QALYs at a cost of €2985 for pharmacotherapy alone. 
Therefore, ACARIZAX produced an extra 0.66 QALYs at 
an incremental cost of €2673, which equates to an ICER 
of €4041. This is substantially lower than the €40,000 
threshold adopted for the analysis.
Indirect costs were also incorporated based on the 
administration of the WPAI during the final month of 
the MT-04 treatment maintenance period. Following 
this assessment it was found that asthma caused 0.8 and 
1.6  % of work time to be missed for ACARIZAX and 
pharmacotherapy respectively. Based on an average of 
1371  h worked per year in Germany [19] and an aver-
age work day of 7.5 h, it was estimated that 1.51 days per 
year would be missed with ACARIZAX compared with 
3.02  days with pharmacotherapy. Klussman and col-
leagues have previously estimated the cost per sick day 
in Germany is €93.69 [20]. Therefore, the total annual 
indirect costs were estimated to be €141 for ACARI-
ZAX and €283 for pharmacotherapy. When these costs 
were included the total per patient costs rose to €6760 
for ACARIZAX and €5188 for pharmacotherapy respec-
tively, with overall incremental costs reducing from 
€2673 to €1572.
Within the two additional scenarios, the ICER 
remained below €40,000. For scenario one (i.e. the unfa-
vourable scenario) the ICER increased from the base 
case value to €14,091, as the QALY gain reduced to 0.19. 
Alternatively, for scenario two (i.e. scenario testing the 
disease-modifying effect) the ICER was lower than that 
produced in the base case, being as it was €3832, and this 
was due to a QALY gain of 0.70. Within both scenarios, 
the inclusion of indirect costs had no impact on the 
direction of the results but did affect the magnitude, with 
the incremental costs reducing.
The results of the sensitivity analyses indicate that the 
model’s results are sensitive to changes in two key input 
parameters. If, during years two and three of treatment, 
ACARIZAX patients have a decline in health of 2  % or 
more, or if pharmacotherapy patients have an improve-
ment in health of 5 % or more during years 6–9, then the 
ICER increases above the threshold value of €40,000. For 
all remaining parameters, the changes had no impact on 
the model’s conclusions.
Discussion
The cost-utility analysis illustrates that, over a nine year 
time horizon, ACARIZAX plus pharmacotherapy is cost-
effective compared with placebo plus pharmacotherapy, 
in HDM allergic asthma patients not well controlled by 
ICS and associated with mild to severe allergic rhinitis 
in a German setting. The deterministic sensitivity analy-
ses show that there is a degree of uncertainty regarding 
the results of the analysis, given modest changes in two 
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input parameters impacted on the cost-effectiveness of 
ACARIZAX (as measured by the ICER). If patient health 
declines at a rate of 2 % or higher during the 3 years of 
treatment with ACARIZAX, then it can no longer be 
considered a cost-effective treatment option at the given 
threshold value. However, evidence regarding AITs indi-
cates that the efficacy of these treatments may be sus-
tained for the duration of treatment, and beyond [12–15]. 
Therefore, it is unlikely that the health of ACARIZAX 
patients will decline during the treatment period. Simi-
larly, if patient health with pharmacotherapy improves 
during years 6–9 then ACARIZAX is no longer cost 
effective. However, this improvement is unlikely given 
the applicable patient population, as they are patients 
whose symptoms are uncontrolled by pharmacotherapy.
The analysis was conducted based on the results of 
a single RCT and there are certain limitations with this 
approach. In particular, healthcare utilisation is based 
on resource use data collected solely within MT-04, 
with costs specific to Germany applied to this data. This 
means the values used in the analysis may not be reflec-
tive of clinical practice, as the resource use within the 
trial was protocol driven, and certain resources required 
by allergic asthma patients may not have been captured 
as they were not recorded in the trial. For example, phar-
macotherapy patients received more clinical supervision 



















Scenario Utility Change – ACARIZAX Utility Change - Pharmacotherapy
Years 2–3 Years 4–5 Years 6–9 Years 2–3 Years 4–5 Years 6–9
Base case +5% 0% −5% 0% 0% −5%
1 0% 0% −5% 0% 0% −5%
2 5% 0% 0% 0% 0% 0%
Fig. 1 Graphical representation of change in patient utility over time, for each of the three scenarios assessed. Within all three scenarios, utility 
scores were based on results from the end of the treatment maintenance period in MT‑04. For all remaining years, utility scores were altered via an 
annual rate of change, to see the impact long‑term changes in patient outcomes had on the results. The rates of change in each scenario are given 
here in table
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than can be expected in clinical practice. This may have 
reduced the total number of contacts with the healthcare 
system outside of the trial protocol (e.g. emergency room 
visits). Related to this, better overall supervision and the 
Hawthorne effect (i.e. patients modifying their behaviour 
as they were being monitored) may have led to a clinical 
gain that will not be found in practice, and patient health 
may have improved regardless of treatment as outcome 
measures naturally tended towards the population mean 
(i.e. regression to the mean). Despite the limitations of 
undertaking economic evaluations alongside a single 
RCT such an approach is becoming more common, with 
some funders now specifically requesting these evalu-
ations alongside RCTs, as they allow for an early stage 
estimate of cost-effectiveness (i.e. before use has become 
widespread in clinical practice) [22]. Furthermore, 
MT-04 was a large-scale trial conducted across several 
countries with multiple investigators. Therefore, the 
treatment effect of ACARIZAX should have been appro-
priately captured across a wide population group.
The analysis covers a nine year time horizon with the 
assumption that the health (i.e. utility) of ACARIZAX 
patients remains stable in the 2  years post-treatment, 
which implies some form of disease-modifying effect. 
However, there are no long-term efficacy data to prove 
this effect, with the assumption based on the findings of 
other AITs. Therefore, to ensure that ACARIZAX does 
not gain an unfair advantage, it was also assumed that 
pharmacotherapy patients remained stable during this 
period and in the longer term that both ACARIZAX and 
pharmacotherapy patients have a decline in health during 
years 6–9. Furthermore, at the willingness-to-pay thresh-
old of €40,000, ACARIZAX was cost-effective compared 
with pharmacotherapy at each of the 9 years included in 
the analysis indicating it is cost-effective even when long-
term extrapolation of the data is not undertaken. In the 
future, further health economic evaluations could be 
undertaken should long-term, real world data become 
available (e.g. registry studies). This evaluation could 
estimate the true benefits of ACARIZAX, particularly if 
a disease-modifying effect has been proven in practice, 
and the impact of the placebo effect observed in MT-04 
could also be assessed. If a disease-modifying effect can 
be proven in practice then this analysis may prove to 
be conservative estimation of the cost-effectiveness of 
ACARIZAX.
AIT options, such as ACARIZAX, can be associated 
with adverse events that will impact on patient qual-
ity of life and overall treatment costs. Such events were 
not formally included in this analysis as the rate of seri-
ous adverse events was very low (less than 1 % for 12 SQ 
HDM patients) in MT-04 and because there was no clear 
difference in the rate of serious adverse events between 
ACARIZAX and placebo patients. It should be noted that 
the cost of asthma exacerbations were also not included 
in the analysis. However, ACARIZAX has a positive 
impact on exacerbations as shown via the quantification 
of number needed to treat (NNT) to avoid any moderate 
to severe exacerbation, which was measured during the 
ICS reduction period of trial, and found to only be 10 for 
ACARIZAX [21]. This beneficial impact of ACARIZAX 
was not quantified in the analysis.
In the future it may be pertinent to compare ACARI-
ZAX with other AITs, which are considered standard 
care in Germany. It was, however, not feasible to compare 
ACARIZAX with all potential AITs in a double-blinded, 
controlled trial. Furthermore, currently, there are no 




















Fig. 2 Overview of the structure of the analysis. A cost utility analysis was undertaken to assess the impact of ACARIZAX on allergic asthma patients 
taking pharmacotherapy. Two treatment options were included; ACARIZAX plus pharmacotherapy, and placebo plus pharmacotherapy. A nine year 
time horizon was used, with ACARIZAX patients given treatment for 3 years. Over the nine year time horizon ACARIZAX patients accumulated 6.16 
QALYs on average, at a mean cost of €5658, compared to an average of 5.50 QALYs at a mean cost of €2985 for pharmacotherapy only patients. 
This equates to an incremental cost‑effectiveness ration (ICER) of €4041, substantially lower than the threshold value of €40,000 adopted here. This 
indicates that ACARIZAX is a cost‑effective treatment option
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asthma has been demonstrated using similar design; 
hence comparison between ACARIZAX and other AIT is 
not possible [23].
Conclusion
The analysis presented here indicates that ACARIZAX 
in addition to pharmacotherapy is a cost-effective treat-
ment option compared to pharmacotherapy alone in 
HDM allergic asthma patients not well controlled by ICS 
and associated with mild to severe allergic rhinitis. If a 
disease-modifying effect can be proven the results of this 
analysis may underestimate the true benefits of ACARI-
ZAX as conservative assumptions were used to predict 
long-term patient outcomes.
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